Quoin reports positive interim Phase 2/3 data for QRX003 in Netherton syndrome trial
QNRX•Safety and next milestones
No treatment-related serious safety issues were reported, reducing near-term clinical and regulatory risk for the program.
Full enrollment is targeted by end-2026, with topline results expected in Q2 2027, a key catalyst for the stock.
Interim Phase 2/3 results show efficacy signal
Quoin Pharmaceuticals posted interim Phase 2/3 results for QRX003 lotion in Netherton syndrome, based on the first six patients.
The analysis showed a meaningful share of patients improved on clinician-rated skin assessments, supporting the product’s efficacy signal.
Patients also reported improvement in itch, pointing to potential symptomatic benefit alongside physician-assessed changes.
